Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece.
Curr Pharm Des. 2013;19(21):3827-40. doi: 10.2174/13816128113199990307.
Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2)) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.
心血管疾病是西方世界发病率和死亡率的主要原因。然而，目前可用的风险评估工具似乎经常低估风险，特别是对于中危患者。考虑到社会经济成本，正确识别从中危获益更多强化治疗的患者至关重要。大量的实验和观察性研究提供了支持，表明脂蛋白相关磷脂酶 A2（Lp-PLA2）和分泌型磷脂酶 A2（sPLA2）以及高敏 C 反应蛋白（hsCRP）是心血管风险的有用生物标志物。特别是，Lp-PLA2）也被作为药物靶点进行了研究，我们正在急切地等待正在进行的 III 期临床试验的结果。在这篇综述中，我们讨论了关于这些生物标志物的优缺点的现有文献。
